ArticlePharmacoepidemiology and drug safety2025
Trends in the Dispensing of Oral Anti-Cancer Medications Across Australia Over 10 Years.
Article in Pharmacoepidemiology and drug safety, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeOral anti-cancer medications (OAMs) are easily administered yet high-risk treatments. Few studies have investigated national and subnational trends in OAM dispensing. We aimed to examine 10-year trends in Australia's OAM dispensing at the national level as well as by state/territory and medication type/class.
methodsAggregate data on Australia's OAM dispensing and population for 2014-2023 were sourced from Services Australia and the Australian Bureau of Statistics, respectively. Annual OAM dispensing rates (counts per 100 000 population) were calculated overall as well as by state/territory and medication type/class. Percentage change (Δ) in dispensing rates from 2014 to 2023 was determined. Where valid, Mann-Kendall trend tests were performed.
resultsAustralia-wide from 2014 to 2023, dispensing counts per 100 000 population for any OAMs increased nonlinearly from 3 475 to 3 930 (+Δ13%), hormonal OAMs decreased nonlinearly from 2 659 to 2 225 (-Δ16%), and non-hormonal OAMs exhibited a significant (p < 0.05) near-linear upward trend from 816 to 1 705 (+Δ109%). This coincided with a significant upward trend in the number of unique non-hormonal OAMs dispensed Australia-wide (+Δ187%). Percentage changes in non-hormonal OAM dispensing rates were greatest for protein kinase inhibitor (PKI) dispensing Australia-wide (+Δ232%), with a significant, near-linear upward trend from 286 to 950, and non-hormonal OAM dispensing in South Australia (+Δ141%), with a significant, near-linear upward trend from 820 to 1972.
conclusionsAustralia's non-hormonal OAM dispensing increased over 2014-2023, mostly for PKIs. This likely reflects rising availability of and prescriber/patient demand for these medications, suggesting scope to pilot and expand OAM adherence and safety initiatives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.